In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: SCH 663366; Zokinvy (Eiger Biopharmaceuticals)
- INDICATIONS:
Reduction of the risk of mortality in Hutchinson-Gilford Progeria Syndrome. For treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.
- CLASS: Farnesyltransferase inhibitor
- HALF-LIFE: approximately 4–6 hours
- FDA APPROVAL DATE: 11/20/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atorvastatin, CYP2C9 inhibitors, CYP3A inducers, CYP3A inhibitors, Grapefruit Juice, Loperamide, Lovastatin, Midazolam, Simvastatin - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the risk to a fetus and to use effective contraception.
Based on animal studies, may impair fertility. Advise females and males of the adverse reproductive potential of lonafarnib.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
